CN102357134B - Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof - Google Patents
Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof Download PDFInfo
- Publication number
- CN102357134B CN102357134B CN 201110331011 CN201110331011A CN102357134B CN 102357134 B CN102357134 B CN 102357134B CN 201110331011 CN201110331011 CN 201110331011 CN 201110331011 A CN201110331011 A CN 201110331011A CN 102357134 B CN102357134 B CN 102357134B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- preparation
- subsequent use
- above ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 206010008132 Cerebral thrombosis Diseases 0.000 title claims abstract description 17
- 201000001429 Intracranial Thrombosis Diseases 0.000 title claims abstract description 17
- 208000024827 Alzheimer disease Diseases 0.000 title abstract description 6
- 229930003944 flavone Natural products 0.000 claims abstract description 23
- 235000011949 flavones Nutrition 0.000 claims abstract description 23
- 229930187479 gypenoside Natural products 0.000 claims abstract description 21
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000000843 powder Substances 0.000 claims description 52
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 47
- 241000180649 Panax notoginseng Species 0.000 claims description 47
- 241000628997 Flos Species 0.000 claims description 36
- 210000000582 semen Anatomy 0.000 claims description 36
- 238000000605 extraction Methods 0.000 claims description 23
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 22
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 22
- 150000002212 flavone derivatives Chemical class 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 18
- 239000006071 cream Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 238000013467 fragmentation Methods 0.000 claims description 15
- 238000006062 fragmentation reaction Methods 0.000 claims description 15
- 239000012567 medical material Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 14
- 238000003809 water extraction Methods 0.000 claims description 14
- 241000219780 Pueraria Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 abstract description 2
- 235000003181 Panax pseudoginseng Nutrition 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000112528 Ligusticum striatum Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 150000002213 flavones Chemical class 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 29
- 239000008280 blood Substances 0.000 description 29
- 230000000694 effects Effects 0.000 description 19
- -1 flavone compound Chemical class 0.000 description 18
- 241000700159 Rattus Species 0.000 description 14
- 206010013786 Dry skin Diseases 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 9
- 230000003064 anti-oxidating effect Effects 0.000 description 9
- 210000001772 blood platelet Anatomy 0.000 description 9
- 230000006870 function Effects 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 230000002490 cerebral effect Effects 0.000 description 7
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002932 luster Substances 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 210000005013 brain tissue Anatomy 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 102100033639 Acetylcholinesterase Human genes 0.000 description 2
- 108010022752 Acetylcholinesterase Proteins 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 239000003172 expectorant agent Substances 0.000 description 2
- 230000003419 expectorant effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003627 anti-cholesterol Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Numbering | Inventory (g) | Paste volume (g) | Content (%) |
1 | 720 | 743.50 | 0.44 |
2 | 720 | 728.10 | 0.48 |
3 | 720 | 733.35 | 0.46 |
Concentration of alcohol | Character | Soft material viscosity | The granule homogeneity | Pellet hardness | The tabletting quality |
80% | Color and luster is uneven | Greatly | Generally | Greatly | Poor |
85% | Color and luster is uneven | Greatly | Generally | Greatly | Generally |
90% | Color and luster is consistent | Moderate | Uniform particles | Moderate | Well |
95% | Color and luster is uneven | Little | Generally | Little | Generally |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110331011 CN102357134B (en) | 2011-10-27 | 2011-10-27 | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110331011 CN102357134B (en) | 2011-10-27 | 2011-10-27 | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102357134A CN102357134A (en) | 2012-02-22 |
CN102357134B true CN102357134B (en) | 2013-05-01 |
Family
ID=45582551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110331011 Active CN102357134B (en) | 2011-10-27 | 2011-10-27 | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102357134B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988697A (en) * | 2012-08-21 | 2013-03-27 | 苏州谷力生物科技有限公司 | Composition having antithrombosis effect |
CN102949527A (en) * | 2012-11-23 | 2013-03-06 | 周纯喜 | Traditional Chinese medicinal preparation for treating senile dementia and corresponding preparation method |
CN103083558B (en) * | 2013-01-10 | 2015-07-22 | 山东凤凰制药股份有限公司 | Novel application of traditional Chinese medicine composition for treating cerebral infarction during acute stage and earlier restoration stage |
CN103931792A (en) * | 2014-03-21 | 2014-07-23 | 安徽省怀远县鑫泰粮油有限公司 | Cardiovascular and cerebrovascular disease preventing peanut oil and its preparation method |
-
2011
- 2011-10-27 CN CN 201110331011 patent/CN102357134B/en active Active
Non-Patent Citations (6)
Title |
---|
山楂属植物黄酮成分及其分析方法研究进展;郭永学等;《中成药》;20050131;第27卷(第1期);112-115 * |
文莉等.脑得生抗血栓处方筛选.《中国医院药学杂志》.2008,第24卷(第4期),281-283. |
绞股蓝皂苷对糖尿病肾病大鼠肾组织转化生长因子β1表达的影响;金李君等;《中华中医药学刊》;20070930;第25卷(第9期);1922-1925 * |
脑得生抗血栓处方筛选;文莉等;《中国医院药学杂志》;20080228;第24卷(第4期);281-283 * |
郭永学等.山楂属植物黄酮成分及其分析方法研究进展.《中成药》.2005,第27卷(第1期),112-115. |
金李君等.绞股蓝皂苷对糖尿病肾病大鼠肾组织转化生长因子β1表达的影响.《中华中医药学刊》.2007,第25卷(第9期),1922-1925. |
Also Published As
Publication number | Publication date |
---|---|
CN102357134A (en) | 2012-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103071048B (en) | Traditional Chinese medicine composition for treating alzheimer diseases and preparation method of traditional Chinese medicine composition | |
CN113577230A (en) | Composition for preventing and delaying occurrence and development of senile dementia and application thereof | |
CN102357134B (en) | Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof | |
CN104147345B (en) | A kind of Chinese medicine composition for treating cardiovascular autonomic neuropathy | |
CN103463409B (en) | Traditional Chinese medicine formula for treating heart qi deficiency | |
CN104027428B (en) | Preparation method of traditional Chinese medicine compound and application of traditional Chinese medicine compound in prevention and treatment of senile dementia | |
CN103830436A (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
CN103638304B (en) | One treats migrainous Chinese medicine preparation of liver-Yang sthenia type and preparation method thereof | |
CN105326939A (en) | Traditional Chinese medicine for treating heart and cerebral vusculer diseases | |
CN101274013A (en) | Prescription medicine for curing senile dementia and preparation | |
CN101112498B (en) | Chinese traditional medicine having functions of promoting blood circulation, relaxing vein and strengthening muscles and bones and method for preparing the same | |
CN103933386B (en) | Compound hemophiliac capsule used for treating hemophilia and preparation method thereof | |
CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
CN103768349B (en) | Application in preparation treatment cerebrovascular and relevant disease medicine for the four taste Fructus cinnamomi camphorae preparations | |
CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
CN105435196A (en) | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof | |
CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
CN105998752B (en) | A kind of Chinese medicine composition for the treatment of of vascular dementia | |
CN103623109A (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
CN103585366A (en) | Medicine for treating ischemic hyperlipidemia and preparation method thereof | |
CN103656318B (en) | One treats migrainous Chinese medicine preparation of essential resistance of turbid phlegm type and preparation method thereof | |
CN110179893B (en) | Enema liquid of ten ingredients with ginseng and angelica and preparation process thereof | |
CN102228596A (en) | Pharmaceutical composition and preparation and applications thereof in treating coronary heart disease and angina pectoris | |
CN105125886A (en) | Traditional Chinese medicine composition for preventing and treating diabetes and complications of diabetes | |
CN104258301A (en) | Traditional Chinese medicine composition for treating female climacteric ventricular premature beat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120222 Assignee: Hengshengtang Pharmaceutical Co., Ltd., Xi'an City Assignor: Chen Rende Contract record no.: 2015610000026 Denomination of invention: Medicine for preventing and treating Alzheimer disease and cerebral thrombosis and preparation method thereof Granted publication date: 20130501 License type: Exclusive License Record date: 20150422 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180314 Address after: 710043 Shaanxi province Xi'an city street Shinco Weishen Road No. 1 park on the eighth floor of block B Patentee after: Hengshengtang Pharmaceutical Co., Ltd., Xi'an City Address before: 710043 Shaanxi province Xi'an city street Shinco Weishen Road No. 1 Metro Technology Industrial Park Industrial Park Building 8 floor B block Patentee before: Chen Rende |
|
TR01 | Transfer of patent right |